Cargando…
The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry
BACKGROUND: Immune checkpoint inhibitors (ICIs) are quickly becoming key instruments in the treatment of mismatch repair-deficient (dMMR) colorectal cancers (CRCs). Despite their clinical value, ICIs have several limitations associated with their use. Only approximately 15% of all CRCs have a dMMR s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163547/ https://www.ncbi.nlm.nih.gov/pubmed/35669431 http://dx.doi.org/10.3389/fonc.2022.867658 |
_version_ | 1784719945553149952 |
---|---|
author | Yan, Hongkai Li, Yaqi Wang, Xiaoyu Qian, Juanjuan Xu, Midie Peng, Junjie Huang, Dan |
author_facet | Yan, Hongkai Li, Yaqi Wang, Xiaoyu Qian, Juanjuan Xu, Midie Peng, Junjie Huang, Dan |
author_sort | Yan, Hongkai |
collection | PubMed |
description | BACKGROUND: Immune checkpoint inhibitors (ICIs) are quickly becoming key instruments in the treatment of mismatch repair-deficient (dMMR) colorectal cancers (CRCs). Despite their clinical value, ICIs have several limitations associated with their use. Only approximately 15% of all CRCs have a dMMR status, and the overall response rate of ICIs is approximately 40%. The mechanism of ICI resistance is not clear, and its study is limited by the lack of information available on the characterization of the immune microenvironment during the progression from early- to advanced-stage dMMR CRC. METHODS: We used multiplex immunohistochemistry (mIHC) with two panels, each containing five markers, to simultaneously analyze the proportions of immune microenvironment constituents in 59 patients with advanced-stage dMMR CRC and 24 patients with early-stage dMMR CRC. We detected immune cell–associated signatures in the epithelial and stromal regions and evaluated the predictive value of these immune molecules. Student’s t-tests, Mann–Whitney U tests, Cox proportional hazards regression modeling, univariate Cox modeling, and Kaplan–Meier estimation were used to analyze immune cell proportions and survival data. RESULTS: We observed significantly higher proportions of CD8+ cytotoxic T cells (CD8+) (p = 0.001), CD8+ memory T cells (CD8+CD45RO+) (p = 0.032), and CD4+ regulatory T cells (CD4+FOXP3+) (p = 0.011) in the advanced-stage dMMR CRCs than in the early-stage dMMR CRCs. Furthermore, CD3+ T cells with PD-L1 colocalization (CD3+PD-L1+) (p = 0.043) and CD8+ T cells with PD-L1 colocalization (CD8+PD-L1+) (p = 0.005) were consistently more numerous in patients in the advanced stage than those in the early stage. Our analyses revealed that a high proportion of CD3+PD-1+ T cells was an independent prognostic factor of overall survival (OS) [hazard ratios (HR) = 9.6, p < 0.001] and disease-free survival (DFS) (HR = 3.7, p = 0.010) in patients in the advanced stage. CONCLUSION: High numbers of CD8+ cytotoxic T cells and CD8+ memory T cells, which usually represent a cytotoxic function of the adaptive immune system and possibly enhanced inhibition factors, such as CD4+ regulatory T cells and PD-L1 colocalized T cells, were associated with the transformation of the immune microenvironment from the early stage to the advanced stage in dMMR CRCs. Furthermore, CD3+PD-1+ T cells are a prognostic factor for patients with dMMR. |
format | Online Article Text |
id | pubmed-9163547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91635472022-06-05 The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry Yan, Hongkai Li, Yaqi Wang, Xiaoyu Qian, Juanjuan Xu, Midie Peng, Junjie Huang, Dan Front Oncol Oncology BACKGROUND: Immune checkpoint inhibitors (ICIs) are quickly becoming key instruments in the treatment of mismatch repair-deficient (dMMR) colorectal cancers (CRCs). Despite their clinical value, ICIs have several limitations associated with their use. Only approximately 15% of all CRCs have a dMMR status, and the overall response rate of ICIs is approximately 40%. The mechanism of ICI resistance is not clear, and its study is limited by the lack of information available on the characterization of the immune microenvironment during the progression from early- to advanced-stage dMMR CRC. METHODS: We used multiplex immunohistochemistry (mIHC) with two panels, each containing five markers, to simultaneously analyze the proportions of immune microenvironment constituents in 59 patients with advanced-stage dMMR CRC and 24 patients with early-stage dMMR CRC. We detected immune cell–associated signatures in the epithelial and stromal regions and evaluated the predictive value of these immune molecules. Student’s t-tests, Mann–Whitney U tests, Cox proportional hazards regression modeling, univariate Cox modeling, and Kaplan–Meier estimation were used to analyze immune cell proportions and survival data. RESULTS: We observed significantly higher proportions of CD8+ cytotoxic T cells (CD8+) (p = 0.001), CD8+ memory T cells (CD8+CD45RO+) (p = 0.032), and CD4+ regulatory T cells (CD4+FOXP3+) (p = 0.011) in the advanced-stage dMMR CRCs than in the early-stage dMMR CRCs. Furthermore, CD3+ T cells with PD-L1 colocalization (CD3+PD-L1+) (p = 0.043) and CD8+ T cells with PD-L1 colocalization (CD8+PD-L1+) (p = 0.005) were consistently more numerous in patients in the advanced stage than those in the early stage. Our analyses revealed that a high proportion of CD3+PD-1+ T cells was an independent prognostic factor of overall survival (OS) [hazard ratios (HR) = 9.6, p < 0.001] and disease-free survival (DFS) (HR = 3.7, p = 0.010) in patients in the advanced stage. CONCLUSION: High numbers of CD8+ cytotoxic T cells and CD8+ memory T cells, which usually represent a cytotoxic function of the adaptive immune system and possibly enhanced inhibition factors, such as CD4+ regulatory T cells and PD-L1 colocalized T cells, were associated with the transformation of the immune microenvironment from the early stage to the advanced stage in dMMR CRCs. Furthermore, CD3+PD-1+ T cells are a prognostic factor for patients with dMMR. Frontiers Media S.A. 2022-05-20 /pmc/articles/PMC9163547/ /pubmed/35669431 http://dx.doi.org/10.3389/fonc.2022.867658 Text en Copyright © 2022 Yan, Li, Wang, Qian, Xu, Peng and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yan, Hongkai Li, Yaqi Wang, Xiaoyu Qian, Juanjuan Xu, Midie Peng, Junjie Huang, Dan The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry |
title | The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry |
title_full | The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry |
title_fullStr | The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry |
title_full_unstemmed | The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry |
title_short | The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry |
title_sort | alteration of t-cell heterogeneity and pd-l1 colocalization during dmmr colorectal cancer progression defined by multiplex immunohistochemistry |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163547/ https://www.ncbi.nlm.nih.gov/pubmed/35669431 http://dx.doi.org/10.3389/fonc.2022.867658 |
work_keys_str_mv | AT yanhongkai thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT liyaqi thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT wangxiaoyu thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT qianjuanjuan thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT xumidie thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT pengjunjie thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT huangdan thealterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT yanhongkai alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT liyaqi alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT wangxiaoyu alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT qianjuanjuan alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT xumidie alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT pengjunjie alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry AT huangdan alterationoftcellheterogeneityandpdl1colocalizationduringdmmrcolorectalcancerprogressiondefinedbymultipleximmunohistochemistry |